Vinblastine

Lacher MJ, Yeller W. Cyclophosphamide and vinblastine sulphate in Hodgkins disease during pregnancy. JAMA 1966; 195: 486-488. Lacher MJ. Use of vinblastine sulphate to treat Hodgkin's disease during pregnancy. Ann Intern Med 1964; 61: 113-115. Laegreid L, Olegard R, Wahlstrom J, Conradi N. Abnormalities in children exposed to benzodiazepines in utero. Lancet 1987; 1: 108-109. Laegreid L, Olegard R, Wahlstrom J, Conradi N. Teratogenic effects of Benzodiazepine use during pregnancy. J Pediatrics 1989; 14: 126-131. Laegreid L, Olegard R, Conradi N, et al. Congenital malformations and maternal consumpion of benzodiazepines: a case control study. Develop Med Child Neurol 1990; 32: 432-441. Laegreid L, Hagber G, Lundberg A. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines - A prospective study. Neuropediatrics 1992; 23: 60-67. Lagrew DC Jr, Furlow TG, Hager WD, Yarrish RL. Disseminated herpes simplex virus infection in pregnancy. Successful treatment with acyclovir. JAMA 1984; 252: 2058-2059. Lahat E, Raziel A, Friedler S, et al. Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing-hormone agonist in early pregnancy. Hum Reprod 1999; 14: 2656-2660. Lai CH, Hsueh S, Chao AS, Soong YK. Succesful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br J Obstet Gynaecol 1994; 101: 547-549. Laifer SA, Stiller RJ, Siddiqui DS, et al. Ursodeoxycholic acid for the treatment of intrahepatic cholestasis of pregnancy. J Matern Fetal Med 2001; 10: 131-135. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of Exposure to Selective Serotonin Peuptake Inhibitors During Pregnancy on Serotonergic Symptoms in Newborns and Cord Blood Monoamine and Prolactin Concentrations. Arch Gen Psychiatry 2003; 60: 720 Lajeunie E, Barcik U, Thorne JA, et al. Craniosynostosis and fetal exposure to sodium valproate. J Neurosurg 2001; 95: 778-782. Lalkin A, Loebstein R, Addis A et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. J Obstet Gynecol 1998; 179: 727-730. Lambert B, Lindblad A, Lindsten MM et al. Genotoxic effects of metronidazole in human lymphocites in vitro and in vivo. In: Phillips I e Collier J ed: Metronidazole, Proceedings, Geneva 1979. Lambot M-A, Vermeylen D, Noel J-C. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001; 357: 1619-1620. Lammer EJ, Chen DT, Hoar RM et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-841. Lammer EJ, Cordero JF. Exogenous sex hormone exposure and the risk for major malformations. JAMA 1986; 255: 3128-3132. Lammer EJ, Hayes AM, Schunior A, Holmes LB. Risk for major malformation among human fetuses exposed to isoretinoin 13-cisretinoic acid ; . Teratology 1987; 35: 68A. A dissolution test procedure identified in the pharmacopoeia, generally a one time point dissolution test for immediate-release products and a three or more time points dissolution test for modified release products. Cisplatin, carboplatin, aminoglycosides such as gentamicin ; , drugs affecting liver enzymes that remove vinblastine from your body such as aprepitant, azole antifungals including itraconazole, ketoconazole, voriconazole, macrolide antibiotics including erythromycin, rifamycins including rifabutin.
Control issues with their healthcare providers; women taking this drug should discuss breastfeeding, if relevant. Although sterility has not been reported with this medicine, vinblastine may interfere with production of sperm and this possibility should be kept in mind. Tell your healthcare provider if you have other medical problems, especially: varicella chickenpox ; or recent exposure; gout; kidney stones; herpes zoster shingles infection; liver disease; or nerve or muscle disease. Tell your doctor if you have ever had any unusual or allergic reaction to vincristine. Also tell your healthcare professional if you are allergic to any other substances, such as foods, preservatives, or dyes. Side Effects Needing Medical Attention: If vincristine accidentally seeps out of the vein, it may damage some tissues and cause scarring. Your healthcare provider should be notified right away if redness, pain or swelling at the IV site are noticed. Other effects needing attention are: difficulty breathing, blurred or double vision; constipation; difficulty walking; drooping eyelids; side or stomach pain; headache; jaw pain; joint pain; numbness or tingling in fingers and toes; pain in fingers and toes; muscle pain; stomach cramps; bed-wetting; convulsions or seizures; dizziness or lightheadedness when getting up from a lying or sitting position; lack of sweating; loss of appetite; mental depression; painful or difficult urination; unconsciousness; unusual decrease or increase in urination; cough; fever, chills, or sore throat; shortness of breath; sores in mouth or on lips; unusual bleeding or bruising; bloating; diarrhea; weight loss; nausea and vomiting; or skin rash.

HeLa cells treated with vinblastine. The relatively large PC appear to be in the form of helices with prominent gyres. X 1600 . and 8 Cells of A . eucalypti after exposure to vinblastine . When observed by 7 a phase contrast the PC are dense, and 7 b under UV they possess low specific fluorescence . Fig. 8 is another example illustrating specific fluorescence . X 1400.

FIG. 3. Optimum pH for 1, 3 glucanase activity of Ole e 9. The protein was incubated at the indicated pH values under the conditions described in "Experimental Procedures." Absorbance of the colored product was measured at 540 nm and vincristine. Support Our work is currently supported by the Juvenile Diabetes Foundation International, the Deutsche Forschungsgemeinschaft, the National Institutes of Health, and the Elli Lilly Forschung GmbH. Dr. Shelley Nelson is supported by the Alexander von Humboldt Stiftung, and Dr. Kirsten Kuhlbrodt by the Deutsche Forschungsgemeinschaft. Inhibitors were tested in triplicate at a minimum of eight concentrations generally spanning 0.3 to 100 M. Monolayer studies were conducted at 37C in a humidified incubator with shaking 90 rpm ; for either 90 min prazosin, digoxin, and vinblastine ; or 240 min colchicine ; . Markers for Pgp efflux [3H]-amprenavir- separate set of Transwells ; and monolayer integrity Lucifer yellow- every Transwell along with probe substrate ; were included in each experiment. Radiolabeled probes were measured by liquid scintillation counting with Ultima Gold Perkin Elmer, Boston, MA ; scintillation cocktail using a TriCarb T2900 counter Perkin Elmer, Boston, MA ; . The efflux ratio for [3H]-amprenavir test concentration of 3 M ; passed the assay criterion 12 ; and collapsed to unity in the presence of Pgp inhibitor GF120918 demonstrating the functional expression of human Pgp in the monolayers. Amprenavir is a substrate of Pgp but not BCRP or MRPs Olson et al., 2002; Gupata et al., 2004 ; . Lucifer yellow concentration in the receiver compartments was measured by a SpectraMax Gemini cytofluorimeter Molecular Devices, Sunnyvale, CA ; set to an excitation wavelength of 430 nm and an emission wavelength of 538 nm. Values of and vinorelbine. For a description of the L'Oral and TotalFinaElf groups, refer to the registration documents "documents de rfrence" ; issued by each of the two groups. During the financial year, the interest held by the TotalFinaElf group, both directly and indirectly via Elf Aquitaine and its subsidiary Valorisation et Gestion Financire, fell from 26.07% of the capital and 34.90% of the voting rights as of December 31, 2001 to 24.52% of the capital and 33.74% of the voting rights as of December 31, 2002. Since the merger of Sanofi and Synthlabo into Sanofi-Synthlabo on May 18, 1999, TotalFinaElf, via Elf Aquitaine, has disposed of 10.8% of its holdings not covered by the agreement: 2.5% in September 2000, 2.3% in April 2001, and 6% between April 2001 and December 2002!

Velban® vinblastine sulfate for injection , usp ; is vincaleukoblastine, sulfate 1: ; salt.

A 71-year-old man was diagnosed as having severe aortic insufficiency and congestive heart failure. The patient was placed on therapy with digoxin and furosemide. Over the next 3h years, he had several hospitalizations for shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema, which responded to increasingly higher dosages of digoxin and diuretic drugs. The patient was referred for further cardiac evaluation. Examination revealed a dyspneic elderly man with heart rate of 76 beats per minute and blood pressure of 110 70 mm Hg. A 10 cm jugular venous distension was present above the sternal angle. Bibasilar pulmonary rales were audible. Cardiac examination revealed cardiomegaly, a loud pulmonic closure sound, S3 and S4 gallop rhythms, a grade 2 6 systolic ejection murmur, and a diastolic murmur along the left sternal border. The span of the liver was 12 cm. Peripheral edema was also present. A chest x-ray film displayed massive cardiomegaly and interstitial pulmonary congestion. An electrocardiogram demonstrated left ventricular hypertrophy. Cardiac catheterization revealed high right ventricular 55 12 mm pulmonary arterial 55 30 mm and pulmonary capillary wedge 27 mm Hg ; pressures. The aortic pressure was 112 70 mm Hg. Left ventriculographic studies showed a markedly enlarged and diffusely hypokinetic left ventricle. The ejection fraction was 10 percent. Moderately severe aortic insufficiency was observed on aortographic studies of the ascending aorta. The patient was considered a high-risk candidate for surgical correction because of poor left ventricular function. Vasodilator therapy with intravenously administered sodium nitroprusside produced an improvement in left ventricular function. The patient was then given a trial with oral therapy with hydralazine. He had a marked increase in cardiac output, a decrease in pulmonary capillary wedge pressure, and a fall in resistances in the systemic and pulmonary vascular beds without major changes in heart rate and blood pressure Table 1 ; . After 72 hours of oral therapy with hydralazine, the patient reported a marked diminution in complaints of fatigue and orthopnea. The intensity of the S3 and S4 gallop rhythm and the murmur of aortic insufficiency decreased and vivelle. Activity than vinblastine. The Spearman correlation coefficient was 0.72 P 0.001 ; , demonstrating close agreement of in vitro sensitivity between these two compounds. Chart 2 displays the sequential path for these experiments. Since the sequential path did not cross either the upper or lower boundary, we conclude with 95% power that there was no statistically significant difference between the in vitro cytotoxic activity of vinzolidine and its parent compound. Table 3 shows the in vitro activity of vinzolidine and vinblastine when the results were expressed as sensitive or resistant. The results were concordant for 83% of the specimens 63% were resistant to both compounds, and 20% were sensitive to both ; . The K statistic was 0.59 P 0.001 by Fisher's exact test ; , indicating that this close agreement could not be explained by.

Obtained using a very toxic dose schedule. In addition, mitomycin has potential pulmonary toxicity. Vindesine has been used widely in trials in patients with esophageal cancer. The overall cumulative response rate among 86 evaluable patients was 22%. The major side effect of vindesine use has been peripheral neuropathy and myelosuppression. In general, however, the drug is well tolerated. Although widely used in combination chemotherapy, neither vinblastine nor vincristine has undergone singleagent phase 2 testing in epidermoid carcinoma of the esophagus. Two trials have studied 5-FU as a single agent; a cumulative response rate of 42% was noted in 36 evaluable patients. In one study, 5-FU was given as a bolus injection at a dose of 500 mg m2 daily for 5 days at 5-week intervals; 4 of 23 patients responded. In a second trial, 13 previously untreated patients received 5-FU at a dose of 300 mg m2 d as a continuous 24-h intravenous IV ; infusion for 6 weeks, prior to definitive radiation therapy, with a response rate of 85%. This marked difference in the reported response rates for the same agent given in different schedules remains unexplained, but may in part reflect extent of disease and performance status. Recently, investigators from Memorial Sloan-Kettering Cancer Center and M.D. Anderson Cancer Center identified paclitaxel as an active agent in both and voriconazole.

Druginfoonline vinblastine news new test suggests source of statin side effects reutershealth ; further reading adult hodgkin lymphoma treatment pdq ; - advanced unfavorable hodgkin lymphoma webmd ; patients are designated as having advanced unfavorable hodgkin ' s lymphoma hl ; if they have clinical stage iii or stage iv disease. Vinblastine Velban ; Bladder 188. Breast 174. , 175. Cutaneous T-Cell Lymphoma 202.1 , 202.2 , 202.8 Head & Neck 140. to 149. , 161. , 195.0 Hodgkin's Lymphoma 201. Immune or Idiopathic Thrombocytopenic Purpura3 287.31 Kaposi's Sarcoma 176. Kidney 189.0, 189.1 Lung 162. Melanoma 172. Neuroblastoma1 160. , 194.0 Non-Hodgkin's Lymphomas 200. , 202. Ovary1 germ cell ; 183.0 and vortex. Despite efforts implicatio new vinblastine fai do event.

More intelligent use of antibiotic therapy in every case of infertility. This regret, along with all the new things we've learned since 1991 about infertility, microbiology, antibiotic therapy, and disease transmission, have motivated me to write the book you're reading now. If Fertile vs. Infertile can be said to have a single, most important purpose, it is to urge you to seek the best antibiotic therapy applicable to your particular case of infertility. You will need to take on responsibility for the search yourself, because most doctors and clinics don't automatically guide you in that direction. This chapter, based on my own practice, offers you guidelines and examples that will help you to discuss possible infectious problems and antibiotic solutions with any doctors and clinics that you consult. To prepare you in advance to avoid feeling confused or uninformed, it also introduces you to specific medical concerns and procedures, expressed in technical language, that may come up in these discussions. For your convenience, the chapter is divided into two sections. Part One focuses primarily on the tricky diagnostic process: combining scientific inquiry with detective work, intuition, and common sense to determine if pathogens are likely to be causing or aggravating your infertility problem. It's an investigation in which you as the patient can play a major role, because so many clues lie in events or conditions that you alone have experienced. Part Two examines the treatment process. As you will see, this stage can be equally tricky, sometimes involving experimentation with more than one promising strategy as unanticipated barriers or setbacks occur along the way. The result, however, is often an amazingly efficient and effective restoration of reproductive capability, leading to an uncomplicated pregnancy and a healthy, full-term baby and vytorin and vinblastine. 1. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human `MDR1' gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987; 84: 30043008. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987; 84: 77357738. Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol. 1993; 24: 7797. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem. 1993; 268: 1499114997. Couture L, Nash JA, Turgeon J. The ATP-binding cassette ABC ; transporters and their implication in drug disposition: A special look at the heart. Pharmacol Rev. 2006; 58: 244 Dean M, Hamon Y, Chimini G. The human ATP-binding cassette ABC ; transporter superfamily. J Lipid Res. 2001; 42: 10071017. Meissner K, Sperker B, Karsten C, et al. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem. 2002; 50: 13511356. Meissner K, Jedlitschky G, Meyer zu Schwabedissen H, et al. Modulation of multidrug resistance P-glycoprotein 1 ABCB1 ; expression in human heart by hereditary polymorphisms. Pharmacogenetics. 2004; 14: 381385. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the bloodbrain barrier and to increased sensitivity to drugs. Cell. 1994; 77: 491502. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the bloodbrain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996; 97: 25172524. Cox DS, Scott KR, Gao H, Eddington ND. Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther. 2002; 302: 10961104. Wijnholds J, Mol CA, van Deemter L, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA. 2000; 97: 74767481. Sasabe H, Kato Y, Suzuki T, Hose M, Miyamoto G, Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J Pharmacol Exp Ther. 2004; 310: 648655. Muramatsu T, Johnson DR, Finch RA, et al. Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol Res. 2004; 14: 331343. Dell'Acqua G, Polishchuck R, Fallon JT, Gordon JW. Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain human multiple drug resistance 1 fusion gene. Hum Gene Ther. 1999; 10: 1269 Wojnowski L, Kulle B, Schirmer M, et al. NAD P ; H oxidase and multidrug resistance protein genetic polymorphism are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005; 112: 37543762. Sridhar R, Dwivedi C, Anderson J, et al. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst. 1992; 84: 16531660. Colombo T, Zucchetti M, D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther. 1994; 269: 2227. Bellamy WT, Peng YM, Odeleye A, et al. Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Anticancer Drugs. 1995; 6: 736743. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemarre M, Sugiyama Y. P-glycoprotein mediates the efflux of quinidine across the bloodbrain barrier. J Pharmacol Exp Ther. 1997; 283: 574580. RESULTS Targeting of the btu1-1 K350M ; allele reveals a role for -tubulin in macronuclear division. Drugs such as vinblastine and paclitaxel alter normal microtubule dynamics and are commonly used to block mitosis. A previous study of wild-type strains demonstrated that microtubule-inhibitory drugs interfere with amitotic macronuclear division in T. thermophila 20 ; . In effort to better understand the role of microtubules in both mitotic and amitotic nuclear division, we examined the fate of micro- and macronuclei in strains expressing either the wild-type CU428 ; or paclitaxel-hypersensitive CU522 ; -tubulin allele btu1-1 K350M ; . In contrast to that in wild-type cells, macronuclear morphology in CU522 btu1-1 ; cultures grown in the absence of paclitaxel showed significant variability, the most obvious differences being cells that had diminutive macronuclei or that lacked macronuclei entirely Fig. 1A and B ; . Inactivation of the macronuclear btu1-1 locus by targeted disruption with several unrelated transgenes restored wild-type macronuclear morphology and division data not shown; see below ; , suggesting that the btu1-1 mutation is responsible for the macronuclear division defect. Other btu1-1 strains CU725 and CU727 ; were similarly defective in macronuclear division. Exacerbation of the btu1-1 K350M ; amacronucleate phenotype at elevated temperatures. The btu1-1 allele confers hypersensitivity to the microtubule-stabilizing drug paclitaxel. Since microtubules are also stabilized by elevated temperatures, we tested the effect of temperature on amacronucleate cell formation. Under standard culture conditions 30C ; , 6% of CU522 cells lacked macronuclei Fig. 1B ; . The frequency of amacronucleate cell formation increased to 12% when growing cultures were maintained at 35C. In contrast, almost no amacronucleate cells were detected at 25C. Irrespective of growth temperature, the amacronucleate phenotype was not detected in wild-type strain CU428, indicating that the temperature-sensitive effect is linked to the btu1-1 allele. Cytophotometric analysis revealed that the macronuclear DNA contents of cells expressing the btu1-1 allele varied considerably compared to those of wild-type cells Fig. 1C ; . When normalized to the postmeiotic 4C micronucleus, the average macronuclear DNA content of CU522 cells cultured at 35C was 117C standard error, 66C; range, 31C to 546C ; . In contrast, the macronuclear DNA contents of wild-type CU428 cells grown under the same conditions were much more moderate mean, 93C; standard error, 13C; range, 64C to 132C ; , with values similar to those reported previously for wild-type T. thermophila strains 11 ; . The wide range in macronuclear DNA contents in CU522 populations indicates that asymmetric macronuclear division occurs frequently. These events not only generate amacronucleate cells but also produce the reciprocal product of asymmetric macronuclear division--cells with an overabundance of macronuclear DNA. The microtubule-stabilizing drugs paclitaxel and DMSO promote amacronucleate cell formation. The dominant btu1-1 allele causes hypersensitivity to the microtubule-stabilizing agent paclitaxel. Since the nuclear division defect in the mutant is exacerbated at elevated temperatures, it seemed likely that microtubule dynamics were being affected at the higher temperatures. To test this hypothesis, we treated cells with increas and abraxane.

8The Swiss proposal errs by incorrectly offering wounding potential as wounding effect in all circumstances. The 1899 Hague Declaration prohibited a projectile designed to offer the same terminal ballistics and commensurate wounds ; at all ranges, wherever the bullet struck the human body. The typical hollow point rifle projectile akin to the so-called `dum-dum' ; nearly always starts expanding within one inch of the skin, at virtually all distances. This is not true of the full-metal jacketed rifle bullet. Modern military small arms ammunition may produce certain terminal ballistics at closer ranges, but only if the projectile travels sufficient distance in the human body. Every projectile fired is subject to myriad variants that may affect its terminal ballistics. 8The Swiss proposal incorrectly relies upon energy transfer and photographs or diagrams of the temporary wound cavity in glycerin soap to make its argument. This contrasts significantly with their normal wounding effect, which according to a Swiss statement ; produces "in tissue simulant narrow [permanent wound] channels. [emphasis supplied]" The Swiss proposal is seriously flawed in its overemphasis on the temporary wound cavity. 8The Swiss proposal incorrectly isolates the wounding potential of small caliber projectiles from other, lawful battlefield wounding mechanisms. While this may be appropriate up to a point, the severity of injuries from small caliber projectiles is far more dependent on placement than other lawful wounding mechanisms. The Swiss proposal is seriously flawed, and is not likely to succeed at this year's UNCCW Review Conference. I will provide a final report on this initiative at next year's National Defense Industrial Association Joint Services Small Arms Symposium. In closing, let me reiterate the value of the DOD weapons review program. We can expect other challenges to other weapons, often times for political or economic rather than humanitarian reasons. Having a weapon review completed and on file is money in the bank. If you are a program manager or industry representative, understand that it is better to obtain this review sooner rather than later. Thank you.
Cesses by isolating mammalian cell mutants defective in microtubule proteins 1-9 ; . Such studies have begun to define the involvement of microtubules in cell growth and division and will soon aid us in understanding how tubulin expression and microtubule assembly are regulated in vivo 10-12 ; . The predominant method for the isolation of mutants with alterations in microtubule proteins has been the use of drug resistance selections. Thus, mutants with alterations in tubulin have been identified among cells selected for resistance to colchicine, Colcemid, griseofulvin, taxol, and other microtubule-interactive drugs. Although this approach has yielded a significant number of mutants with defined alterations in a- and 13-tubulins 1-5 ; , the isolation of permeability mutants in these selections has complicated the mutant analysis and made the isolation of less frequent mutations affecting microtubule function more difficult. Typically, in drug resistance selections, approximately 70-90% of the isolates can be found to have an alteration in membrane permeability M. J. Schibler and F. Cabral, unpublished observations ; . It is not unreasonable to expect similar results in the selection of mutants to other drugs. The elimination of permeability mutants in drug resistance selections, then, would represent a significant improvement in the isolation and characterization of mutants with alterations in the intracellular targets for various drugs. A means for achieving this aim was suggested by studies showing that verapamil, a calcium channel blocking agent, can potentiate the killing of several leukemia and tumor cell lines by the microtubule inhibitors vinblastine and vincristine 13-19 ; . Verapamil exerts this effect by inhibiting the efflux of the inhibitors from cells 14, 18, 20, ; , thus allowing increased intracellular drug concentrations and the resultant cell death. These observations suggested to us that verapamil might enhance our ability to isolate mutants with alterations in a- and 3-tubulin proteins in drug resistance selections. In this communication, we show. Aman is common rice which is produced by the most farmers all over Bengal. One of the main reasons of producing this crop in enormous volume is availability of sufficient rain water. In the spring and winter seasons, shortage of water is the key problem. The farmer faces great difficulty in rabi winter ; season. Boyce 1987 ; observes that, owing to insufficient soil moisture and lack of irrigation, much land remain fallow in the winter season. This means that producing crops in winter heavily depends on the farmer's private irrigation system. So, the farmer, who can afford to irrigate land in winter on his own and produce crop, is financially stronger than the other who cannot. Naturally, the former has a stronger capital base and deserves to be a non-farm entrepreneur. Therefore, in the formulation of hypothesis we stress on the production of boro rice and potato which are produced in winter rabi ; season and accordingly we hypothesize that the farmer, who is producing three crops a year such as aman rice which is a common one ; , boro rice, and potato, has a higher likelihood to be a non-farm entrepreneur. The counterargument may support the alternative hypothesis, i.e. the farmer has a higher likelihood to be a non-farm entrepreneur if he produces less than three crops such as aman rice, boro rice, and potato, than the other who produces these three crops a year. The producer of three crops may be financially stronger than the other producer who is not engaged in the production of the above mentioned three crops in a year. It may be assumed that the rich farmers are engaged in farming throughout the year. And since they are rich and happy with their traditional occupation they do not have urge to occupationally deviate. At the same time, it is also true that the producer of the three crops may have lack of time to be engaged in some activities other than farming. Producing three crops, along with the other minor crops, in different seasons requires much time from the farmer who may not find considerable amount of extra time to think of diversification in non-agriculture. Hence, we hypothesize that the farmer has a higher likelihood to be a non-farm entrepreneur if he produces less than three crops mentioned above. TOS Proc Code 1 J9300 1 J9305 1 J9310 1 J9320 1 J9340 1 J9350 1 J9355 1 J9357 1 J9360 1 J9370 1 J9375 1 J9380 1 J9390 1 J9395 1 J9600 1 J9999 1 K0008 1 K0010 1 K0011 1 K0012 1 K0013 1 K0014 1 K0016 1 K0021 1 K0022 1 K0023 1 K0024 1 K0025 1 K0026 1 K0027 1 K0028 1 K0029 1 K0030 1 K0031 1 K0032 1 K0033 1 K0034 1 K0035 1 K0036 1 K0048 1 K0049 1 K0054 1 K0055 1 K0057 1 K0058 1 K0059 1 K0060 1 K0061 Description GEMTUZUMAB OZOGAMICIN, 5 MG MYL INJECTION, PEMETREXED, 10 MG AL RITUXIMAB, 100 MG RITUXAN ; STREPTOZOCIN, 1 GM ZANOSAR ; THIOTEPA, 15 MG THIOPLEX ; TOPOTECAN, 4 MG HYCAMTIN ; TRASTUZUMAB, 10 MG HERCEPTIN ; VALRUBICIN, INTRAVESICAL, 200 MG VINBLASTINE SULFATE, 1 MG VELBA VINCRISTINE SULFATE, 1 MG ONCOV VINCRISTINE SULFATE 2 MG ONCOVI VINCRISTINE SULFATE, 5 MG ONCOV VINORELBINE TARTRATE, PER 10 MG INJECTION, FULVESTRANT, 25 MG PORFIMER SODIUM, 75 MG, PHOTOFR NOT OTHERWISE CLASSIFIED, ANTINE CUSTOM MANUAL WHEELCHAIR BASE STANDARD-WEIGHT FRAME MOTORIZED STANDARD-WEIGHT FRAME MOTORIZED LIGHTWEIGHT PORTABLE MOTORIZED P CUSTOM MOTORIZED POWER WHEELCHAI OTHER MOTORIZED POWER WHEELCHAIR DETACHABLE, ADJUSTABLE HEIGHT AR ANTITIPPING DEVICE, EACH REINFORCED BACK UPHOLSTERY SOLID BACK INSERT, PLANAR BACK, SOLID BACK INSERT, PLANAR BACK, HOOK-ON HEADREST EXTENSION BACK UPHOLSTERY FOR ULTRALIGHTWE BACK UPHOLSTERY FOR WHEELCHAIR T FULLY RECLINING BACK REINFORCED SEAT UPHOLSTERY SOLID SEAT INSERT, PLANAR SEAT, SAFETY BELT PELVIC STRAP SEAT UPHOLSTERY FOR ULTRALIGHTWE SEAT UPHOLSTERY FOR WHEELCHAIR T HEEL LOOP, EACH HEEL LOOP WITH ANKLE STRAP, EACH TOE LOOP, EACH ELEVATING LEGREST, COMPLETE ASSE CALF PAD, EACH SEAT WIDTH OF 10, 11, 12, SEAT DEPTH OF 15, 17 OR 18 INCHE SEAT WIDTH 19 OR 20 INCHES FOR H SEAT DEPTH 17 OR 18 INCHES FOR A PLASTIC COATED HANDRIM, EACH STEEL HANDRIM, EACH ALUMINUM HANDRIM, EACH Eff Dt Price PAC PA 11 1 2006 , 317.16 3 NO 7 2006 .59 3 NO 11 1 2006 1.69 3 NO 7 1 2006 3.44 3 NO 7 1 2006 .16 3 NO 11 1 2006 3.08 3 NO 7 1 2006 .11 3 NO 2 13 2006 ##TEXT##.01 5 NO 7 1 2006 .01 3 NO 7 1 2006 .14 3 NO 7 1 2006 .29 3 NO 11 1 2006 .43 3 NO 7 1 2006 .51 3 NO 7 1 2006 .86 3 NO 7 1 2006 , 505.40 3 NO 1 2004 ##TEXT##.01 5 NO 1 2002 INVALID N NO 10 2006 NC 9 NO 2006 NC 9 NO 2006 NC 9 NO 2002 INVALID N NO 10 2006 NC 9 NO 2004 INVALID N NO 7 2003 INVALID N NO 4 2004 INVALID N NO 1 2005 INVALID N NO 1 2005 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 7 2003 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 4 2004 INVALID N NO 1 2005 INVALID N NO 1 2005 INVALID N NO 1 2005 INVALID N NO.